Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.62 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485406 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL8080979 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28377172 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28373438 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28372334 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL30485379 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28372331 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL17452195 | 0.94 | CTSS (0.63) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL8073093 | 0.94 | REN (0.68) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL18171935 | 0.94 | REN (0.68) | RENCTSSCTSKPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117683080-A | Synthesis method of carfilzomib key intermediate | 湖南华腾制药有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117683080-A | Synthesis method of carfilzomib key intermediate | 湖南华腾制药有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-110964085-B | Preparation method of carfilzomib and derivatives thereof | 扬子江药业集团有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3297678-B1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LTD (IN) | 2021-07-07 | — | — | EP | disclosed |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| CN-110964085-A | Preparation method of carfilzomib and derivatives thereof | 扬子江药业集团有限公司 | 2020-04-07 | — | — | CN | disclosed |
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-01-28 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-07-30 | — | — | US | disclosed |
| US-10253066-B2 | Process for purification of Carfilzomib | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2019-04-09 | — | — | US | disclosed |
| EP-2207791-B1 | CRYSTALLINE PEPTIDE EPOXY KETONE PROTEASE INHIBITORS AND THE SYNTHESIS OF AMINO ACID KETO-EPOXIDES | ONYX THERAPEUTICS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8129346-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090215093-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215093-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090105156-A1 | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides | PROTEOLIX, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2005105827-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | OPRL1, PNMT, HTR1A | REN 853/4885CTSS 3195/4885CTSK 4479/4885 |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | REN 17/4885CTSS 132/4885CTSK 252/4885 |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | REN 17/4885CTSS 132/4885CTSK 252/4885 |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | REN 592/4885CTSS 70/4885CTSK 92/4885 |
| US-10253066-B2 | Process for purification of Carfilzomib | PSMB5, PSMA5, PSMB2 | REN 60/4885CTSS 923/4885CTSK 894/4885 |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SF3B5, PRCP, GBA1 | REN 17/4885CTSS 132/4885CTSK 252/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | REN 826/4885CTSS 100/4885CTSK 128/4885 |
| US-20090105156-A1 | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides | PREP, ANPEP, DNPEP | REN 36/4885CTSS 31/4885CTSK 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.